Abstract
Background Some payors and clinicians require alcohol abstinence for direct-acting antiviral (DAA) therapy for chronic hepatitis C virus (HCV) infection.
Objective To evaluate whether alcohol use at DAA treatment initiation was associated with decreased odds of sustained virologic response (SVR).
Design Observational cohort study using electronic health records.
Setting US Department of Veterans Affairs (VA), the largest integrated national healthcare system that provides unrestricted access to HCV treatment.
Patients All patients born between 1945 and 1965 who were dispensed DAA therapy between 1 January 2014 and 30 June 2018.
Measurements We used multivariable logistic regression to estimate odds ratios (ORs) and 95% confidence intervals (CIs) of SVR associated with alcohol category. SVR was defined as undetectable HCV RNA ≥12 weeks after completion of DAA therapy. Alcohol category was determined using information on alcohol use disorder diagnoses and Alcohol Use Disorders Identification Test - C (AUDIT-C) at DAA initiation.
Results Among 69,229 patients who initiated DAA therapy (mean age 63 years; 97% men; 50% non-Hispanic White; 41% non-Hispanic Black; 85% HCV genotype 1), 65,355 (94.4%) of patients achieved SVR. After multivariable adjustment, we found no difference in SVR across alcohol use categories (lowest OR 0.92, 95% CI 0.82-1.04). There was no evidence of interaction by stage of hepatic fibrosis measured by FIB-4 (p-interaction=0.3001).
Limitations Predominately male population.
Conclusion Alcohol use was not associated with lower odds of SVR, suggesting that DAA therapy should not be withheld due to alcohol use. Restricting access to DAA therapy based on alcohol use creates an unnecessary barrier to patients and challenges HCV elimination goals.
Funding source National Institute on Alcohol Abuse and Alcoholism
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the National Institute on Alcohol Abuse and Alcoholism (U01-AA026224, U24-AA020794, U01-AA020790, U10-AA013566). The funders had no role in considering the study design or in the collection, analysis, interpretation of data, writing of the report, or decision to submit the article for publication.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the institutional review boards of Yale University (ref #1506016006) and VA Connecticut Healthcare System (ref #AJ0013). It has been granted a waiver of informed consent and is compliant with the Health Insurance Portability and Accountability Act.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Due to US Department of Veterans Affairs (VA) regulations and our ethics agreements, the analytic data sets used for this study are not permitted to leave the VA firewall without a data use agreement. This limitation is consistent with other studies based on VA data. However, VA data are made freely available to researchers with an approved VA study protocol. For more information, please visit https://www.virec.research.va.gov or contact the VA Information Resource Center at VIReC{at}va.gov.
